IgA nephropathy (IgAN), also known as Berger's disease, is a B-cell-mediated kidney disease where abnormal immune complexes accumulate in the kidneys, causing damage to the glomeruli (small filters inside the kidneys).
It is estimated that there are about 150,000 to 200,000 people in the United States with IgAN. At least 50% of IgAN patients progress to end-stage kidney disease within 20 years, requiring dialysis or a kidney transplant. Calliditas Therapeutics' Tarpeyo, Travere Therapeutics' Filspari, Otsuka's Voyxact, and Novartis' Fabhalta and Vanrafia are some of the FDA-approved therapies for IgA nephropathy.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.